Seeking Clues to ResMed (RMD) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Insights - Analysts project ResMed's quarterly earnings to be $2.04 per share, reflecting a year-over-year increase of 27.5% [5] - Total revenue is expected to reach $1.21 billion, marking a 7.5% increase from the same quarter last year [5] Revenue Estimates - The estimated revenue for 'U.S., Canada, and Latin America - Devices' is $416.07 million, indicating a 7.5% increase from the prior-year quarter [2] - 'Combined Europe, Asia, and other markets - Masks' is projected to be $118.76 million, showing a 10.6% increase from the year-ago quarter [3] - The total revenue for 'U.S., Canada, and Latin America' is estimated at $719.40 million, reflecting an 8.9% year-over-year change [4] - 'Global revenue - Devices' is expected to be $646.02 million, suggesting a 7.2% increase year over year [6] - 'U.S., Canada, and Latin America - Masks' is forecasted to reach $303.33 million, indicating a 10.8% year-over-year change [7] - The consensus for 'Global revenue - Total Sleep and Respiratory Care' stands at $1.07 billion, representing an 8.6% increase from the year-ago quarter [9] - 'Combined Europe, Asia, and other markets - Devices' is projected to be $229.95 million, reflecting a 6.9% year-over-year change [10] - 'Global revenue - Software as a Service' is expected to reach $152.24 million, indicating a 9.8% increase from the prior-year quarter [13] - 'Combined Europe, Asia, and other markets - Total Sleep and Respiratory Care' is estimated at $348.71 million, showing an 8.1% increase from the year-ago quarter [14] - 'Global revenue - Masks' is projected to be $422.09 million, reflecting a 10.8% increase from the year-ago quarter [15] Analyst Revisions - Over the past 30 days, the consensus EPS estimate has been adjusted upward by 0.2%, indicating a reassessment of projections by covering analysts [11] - Analysts emphasize that understanding key metrics beyond consensus earnings and revenue estimates can provide a more comprehensive view of business performance [12] Market Performance - ResMed shares have increased by 2.9% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [16]